跳至主要内容
临床试验/NCT00411866
NCT00411866已完成1 期

Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2006年10月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
36
试验地点
1
主要终点
Blood sampling over period of 336 hours post dosing with SB-773812

研究概览

简要总结

The purposes of this study are to determine if there is a difference in how SB-773812 is distributed through the bloodstream before and after multiple doses of ketoconazole have been given and to determine if there is a difference in how safe and well tolerated SB-773812 is when given on its own and given with ketoconazole.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Subjects receiving ketoconazole for 8 days

Experimental

In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.

干预措施: SB773812 (Drug)

Subjects receiving ketoconazole for 8 days

Experimental

In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.

干预措施: Ketoconazole (Drug)

Subjects receiving ketoconazole for 14 days

Experimental

In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.

干预措施: SB773812 (Drug)

Subjects receiving ketoconazole for 14 days

Experimental

In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.

干预措施: Ketoconazole (Drug)

结局指标

主要结局

Blood sampling over period of 336 hours post dosing with SB-773812

时间窗: over period of 336 hours post dosing

次要结局

  • Safety: ECG, vital signs, adverse events, clinical labs over 48 hours post SB-773812 dosing.(over 48 hours post SB-773812 dosing.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验